鼠精子抗原Sp17与IL-5融合蛋白的克隆表达及其免疫性避孕效研究
|
摘要
随着基因重组技术的发展和人们对生殖分子生物学的深入认识,免疫性避孕疫苗的研究是将来避孕节育研究的重要方向,免疫性避孕疫苗可能成为控制人口过度增长的理想措施。针对精子/睾丸抗原的免疫性避孕疫苗因可能适用于两性,而一直受到研究者的青睐。目前在利用精子抗原开发避孕疫苗的研究中,虽然对某些特异性精子蛋白抗原及表位多肽进行了免疫避孕效应研究,但尚未取得满意的结果。主要可能有以下两个方面的原因造成:1、精子/睾丸抗原为自身蛋白,抗原性弱;2、生殖道粘膜免疫应答水平低下,未能产生足够有效的特异抗体滴度。因此,增强生殖道特异抗体反应是提高精子抗原避孕效应的一个新的切入点。而生殖道粘膜诱发抗精子蛋白特异抗体的关键则是寻找合适的靶抗原、免疫途径和免疫佐剂。
精子蛋白抗原必须具备睾丸/精子特异性并参与精卵相互作用的特性。其中精子表面蛋白Sp17在人和各种哺乳动物如兔、小鼠及灵长类动物中的精母细胞、精细胞和睾丸/精子中表达,是一种高度保守的哺乳动物蛋白。鼠、兔和人的Sp17有61%的同源性,而人与狒狒有97%的同源性。在受精过程中,sp17通过与卵细胞透明带表面的糖蛋白、乙酰肝素和葡聚糖等结合参与顶体反应来促进受精。因此,Sp17是受精过程的关键分子之一,是开发避孕疫苗理想的侯选抗原。
要使合适的抗原产生理想特异的有效粘膜免疫应答必须选择合适的免疫途径和免疫佐剂,其中粘膜免疫是近来有关免疫途径研究的一个热点。一个粘膜部位的免疫反应可以诱发远隔部位粘膜的免疫反应,是粘膜疫苗发挥作用的基础。在生殖道性传播疾病的免疫研究中,鼻内免疫产生的阴道特异IgA和血清特异IgG抗体反应强于阴道或口服接种途径。鼻粘膜免疫不仅诱导出多个粘膜部位尤其是生殖道的抗体反应,且能诱导系统免疫反应,并可显著降低免疫原用量,说明鼻内免疫对抗原较为敏感,尤其是蛋白类抗原。多数疫苗经肌肉、皮下、腹腔或真皮注射,主要诱导系统免疫,诱导粘膜免疫反应的作用弱。因此,对于避孕疫苗来说,鼻内免疫可能是一种比较合适的途径。但大多数可溶性蛋白抗原在未给予佐剂的条件下经鼻内免疫后诱导的免疫反应水平较低,粘膜免疫中要求使用粘膜免疫佐剂来增强精子抗原的免疫原性和诱导所
Being applicable to both sexes, immunological contraceptive vaccine, whose target is spermAestis antigens, has been always drawing immense attention from researchers. In current research on developing contraceptive vaccine using sperm antigens, major focuses are as follow: 1.To screen, identify, isolate, clone and sequence fertility- or infertility-related specific sperm/testis antigen genes and to determine the key active epitopes using various methods. 2. To obtain needed proteins by analytic methods, synthesis or DNA recombination techniques, and 3.To investigate the immunological contraceptive effects of certain specific sperm protein antigens and epitope peptides. However, no satisfactory contraceptive effects have been found yet, and the case is also true with the researches on sperm protein Sp17. The main causes involved are: 1.Being autologous proteins, sperm/testis antigens have weak antigenicity; 2. There are inadequate and ineffective specific antibody titers produced due to low levels of immune response in mucosa of the reproductive tract. Since the titers of specific antibodies in the reproductive tract are closely related to fertility, the design of contraceptive vaccines should aim at effectively triggering mucosal immune responses in the reproductive tract. Therefore, it will be a new direction to enhance contraceptive effects of sperm antigens by reinforcing specific antibody responses in the reproductive tract. The key factors of inducing specific anti-sperm protein antibodies in mucosa of the reproductive tract include appropriate target antigens, immunization routes and immunological adjuvants.A contraception vaccine based on sperm antigens must provided with being expressed specially in the testis/sperm,moreover,taking part in interaction of sperm and ovum。 Several sperm specific antigens identified as prospective candidates for immunocontraception are of testicular origin.Sp17 is a key molecul during fertilization . It was originally found to be expressed exclusively in the spermatocyte,sperm cell and testis of humans and a variety of mammals such as rabbit, mouse and primates ,and specificity binds with the
glycoprotein and glucosan of pellucid zone. Sp17 is a highly conserved mammalian protein, Human and mouse and rabbit Spl7 were shown to share 61% homology, Human and macaque Spl7 were shown to share a very high degree of identity (97%).During fertilization,Spl7 takes part in acrosome response by binding with the heparitin of pellucid zone of ovum and enhances the ablity of fertilization. In addition, Spl7 can affect acrosome respones and motoricity of sperm by binding after interaction sit of it's N tip and cAMP-dependence protein kinase Ila regulatory subit binds with protein kinase A anchoring protein.Therefore,Spl7 is a suitable antigen of contraceptive vaccine.Mucosal immunity has become a research highlight over recent years. It stimulates local and remote mucosal and systemic immune responses. Intranasal immunity not only stimulates antibody response in multiple mucosal sites, particulary in the reproductive tract, but also stimulates systemic immune response, thus drawing particular attention from researchers. Administered intramuscularly, subcutaneously, intraperitoneally or intradermally, injections of most vaccines mainly stimulate systemic immunity, rarely stimulating mucosal immune response. Therefore, intranasal immunity will be a prosperous immunization strategy for contraceptive vaccines. However, immunological adjuvants must be used to enhance the immunogenicity of sperm antigens and to stimulate needed types of immune responses in mucosal immunity. Most soluble protein antigens immunized intranasally stimulate low levels of immune responses if not being used with adjuvants. So, the use of immunological adjuvant plays a significant role in mucosal immunity. With regard to antigens, immunization routes and specificity of anti-infection, properties of specific adjuvants may vary essentially. There has been no research report on the intranasal immunization route of sperm antigens and the application of immunological adjuvants at home or abroad.This study for the first time used cytokine IL-5 as the immunological adjuvant for intranasal immunization of sperm protein Spl7. Sperm protein Spl7 was cloned and prokaryotically expressed using genetic recombination technique. cDNA sequence encoding IL-5 protein in mature mice was inserted into prokaryotic expression vector pET/SP17 to construct recombinant expression vector of IL-5-Spl7 fusion gene, and then the IL-5-Spl7 fusion protein was prokaryotically expressed efficiently and purified. Male mice were intranasally immunized with resultant recombinant protein. Then the following data were observed: 1 The titer changes of anti-SP17antibody in serum and the reproductive
tract, 2 The effects on fertility, 3 Pathologic changes of vital organs such as the liver, kidney, spleen, lung, brain, testis and ovary, and 4 Changes in the rates of teratism and micronucleus of sperms in filial generation.The main results and conclusion of the study are as follow:1. cDNA sequence encoding sperm protein Spl7 was amplified from mice testis using RT-PCR. Recombinant plasmid pET/Spl7 was constructed by inserting the gene in the expression vector pET-28a(+) using oriented cloning. Full-length mice IL-5 gene was amplified with plasmid pGEM-l-IL-5 as the template and cloned into pET/Spl7 via the restriction sites of BamH I and Hind HI and linked to the upstream of Spl7 gene via the base sequence encoding the linker YPQD, thus successfully constructing recombinant plasmid pET/IL-5-Spl7. The fusion gene of IL-5-Spl7 was confirmed to meet the design requirements using double enzymatic excision and sequencing.2. The recombinant plasmids pET/Spl7 and pET/IL-5-Spl7 were transfected into E. Coli BL21(DE3). IPTG was used to stimulate gene expression. SDS-PAGE analysis revealed that both Spl7 and IL-5-Spl7 were expressed, and the molecular weight of the proteins were approximately 25kD and 49kD respectively, being approximate to the theoretical values of Spl7 and IL-5-Spl7 recombinant proteins. The purity of recombinant proteins Spl7 and IL-5-Spl7 was 88.9% and 91% respectively after being purified using Ni2+-ANT affinity column. Western blotting confirmed that the expressed proteins were Spl7 and IL-5-Spl7 respectively using anti-his mAb.3. The mice were immunized intranasally with the recombinant proteins and the titers of specific antibodies IgG and IgA in serum and the reproductive tract were determined. At 2 weeks of the primary immunization, Spl7-specific antibody IgG response was present in the mice of the experimental groups. Following immunization, antibody titers increased as the time elapsed and reached a peak at 6 weeks of the primary immunization. The highest levels of induced anti-Spl7 antibody were observed in the IL-5-Spl7 group, reaching 1:12800, which sustained for about 4 weeks before slight decrease. At 2 weeks of the primary immunization, specific antibody IgA was present in mice vaginal irrigation fluid of each experimental group and the levels increased by degrees, reaching peak values at 6 weeks of the primary immunization. The highest levels of antibody were observed in the IL-5-Spl7 group, reaching 1:12800. No Spl7-specific IgG or IgA antibody was detected in the negative control group. Rank sum testing showed that from 4 weeks after the primary
immunization, the titers of specific IgG and IgA antibodies in both the IL-5-Spl7 group and the Spl7+IL-5 group were significantly higher than that in the Spl7 group at the same stage(p<0.05), and that there was no significant difference between the !L-5-Spl7 group and the Spl7+IL-5 group.4. At 10 days of immunization, detection of the proliferation rate of mice splenic lymphocyte and IL-4 and INF- Y secreted by lymphocytes showed that, following immunization of IL-5-Spl7, the proliferation rate of mice splenic lymphocyte increased, so did the IL-4 and INF- Y in supernatant of lymphocyte culture. Moreover, the increase in IL-4 was much more obvious. Analysis of mice serum subtypes revealed that, following IL-5-Spl7 immunization, the ratio of IgGl:IgG2a increased. The above findings suggested that intranasal immunization with IL-5-Spl7 stimulated strong mucosal immunity in the reproductive tract and systemic immune response in mice, which mainly stimulated Tl^-type immune response, helping humoral immune response.5. Following intranasal immunization, the pregnancy rates of the groups IL-5-Spl7, IL5+Spl7, Spl7 decreased to 15.4%, 28.6%, $10% respectively. The number of newborn per birth in each group decreased too, significantly lower than that of the Spl7 group. These findings demonstrated that sperm antigen Spl7 with or without the use of adjuvant stimulated immunological contraceptive effects to certain degrees, but cannot totally block mice reproduction.6. Histologic studies following immunization revealed: 1 There was no apparent pathologic changes in the liver and spleen and no signs of lymphocyte infiltration, 2 There were perivascular spaces in brain, 3 There was no apparent pathologic changes in the kidney and lung, 4 The follicles were morphologically normal and no atrophy occurred, 5 The diameters of testis seminiferous tubules were normal with complete basal lamina, and there were abundant sperms and spermatoblasts of various stages. Micronucleus tests of bone marrow obtained from immunized mice and their offspring showed that there was no significant difference in PCE / NCE and micronucleus rate between the experimental and normal groups.
精子蛋白抗原必须具备睾丸/精子特异性并参与精卵相互作用的特性。其中精子表面蛋白Sp17在人和各种哺乳动物如兔、小鼠及灵长类动物中的精母细胞、精细胞和睾丸/精子中表达,是一种高度保守的哺乳动物蛋白。鼠、兔和人的Sp17有61%的同源性,而人与狒狒有97%的同源性。在受精过程中,sp17通过与卵细胞透明带表面的糖蛋白、乙酰肝素和葡聚糖等结合参与顶体反应来促进受精。因此,Sp17是受精过程的关键分子之一,是开发避孕疫苗理想的侯选抗原。
要使合适的抗原产生理想特异的有效粘膜免疫应答必须选择合适的免疫途径和免疫佐剂,其中粘膜免疫是近来有关免疫途径研究的一个热点。一个粘膜部位的免疫反应可以诱发远隔部位粘膜的免疫反应,是粘膜疫苗发挥作用的基础。在生殖道性传播疾病的免疫研究中,鼻内免疫产生的阴道特异IgA和血清特异IgG抗体反应强于阴道或口服接种途径。鼻粘膜免疫不仅诱导出多个粘膜部位尤其是生殖道的抗体反应,且能诱导系统免疫反应,并可显著降低免疫原用量,说明鼻内免疫对抗原较为敏感,尤其是蛋白类抗原。多数疫苗经肌肉、皮下、腹腔或真皮注射,主要诱导系统免疫,诱导粘膜免疫反应的作用弱。因此,对于避孕疫苗来说,鼻内免疫可能是一种比较合适的途径。但大多数可溶性蛋白抗原在未给予佐剂的条件下经鼻内免疫后诱导的免疫反应水平较低,粘膜免疫中要求使用粘膜免疫佐剂来增强精子抗原的免疫原性和诱导所
Being applicable to both sexes, immunological contraceptive vaccine, whose target is spermAestis antigens, has been always drawing immense attention from researchers. In current research on developing contraceptive vaccine using sperm antigens, major focuses are as follow: 1.To screen, identify, isolate, clone and sequence fertility- or infertility-related specific sperm/testis antigen genes and to determine the key active epitopes using various methods. 2. To obtain needed proteins by analytic methods, synthesis or DNA recombination techniques, and 3.To investigate the immunological contraceptive effects of certain specific sperm protein antigens and epitope peptides. However, no satisfactory contraceptive effects have been found yet, and the case is also true with the researches on sperm protein Sp17. The main causes involved are: 1.Being autologous proteins, sperm/testis antigens have weak antigenicity; 2. There are inadequate and ineffective specific antibody titers produced due to low levels of immune response in mucosa of the reproductive tract. Since the titers of specific antibodies in the reproductive tract are closely related to fertility, the design of contraceptive vaccines should aim at effectively triggering mucosal immune responses in the reproductive tract. Therefore, it will be a new direction to enhance contraceptive effects of sperm antigens by reinforcing specific antibody responses in the reproductive tract. The key factors of inducing specific anti-sperm protein antibodies in mucosa of the reproductive tract include appropriate target antigens, immunization routes and immunological adjuvants.A contraception vaccine based on sperm antigens must provided with being expressed specially in the testis/sperm,moreover,taking part in interaction of sperm and ovum。 Several sperm specific antigens identified as prospective candidates for immunocontraception are of testicular origin.Sp17 is a key molecul during fertilization . It was originally found to be expressed exclusively in the spermatocyte,sperm cell and testis of humans and a variety of mammals such as rabbit, mouse and primates ,and specificity binds with the
glycoprotein and glucosan of pellucid zone. Sp17 is a highly conserved mammalian protein, Human and mouse and rabbit Spl7 were shown to share 61% homology, Human and macaque Spl7 were shown to share a very high degree of identity (97%).During fertilization,Spl7 takes part in acrosome response by binding with the heparitin of pellucid zone of ovum and enhances the ablity of fertilization. In addition, Spl7 can affect acrosome respones and motoricity of sperm by binding after interaction sit of it's N tip and cAMP-dependence protein kinase Ila regulatory subit binds with protein kinase A anchoring protein.Therefore,Spl7 is a suitable antigen of contraceptive vaccine.Mucosal immunity has become a research highlight over recent years. It stimulates local and remote mucosal and systemic immune responses. Intranasal immunity not only stimulates antibody response in multiple mucosal sites, particulary in the reproductive tract, but also stimulates systemic immune response, thus drawing particular attention from researchers. Administered intramuscularly, subcutaneously, intraperitoneally or intradermally, injections of most vaccines mainly stimulate systemic immunity, rarely stimulating mucosal immune response. Therefore, intranasal immunity will be a prosperous immunization strategy for contraceptive vaccines. However, immunological adjuvants must be used to enhance the immunogenicity of sperm antigens and to stimulate needed types of immune responses in mucosal immunity. Most soluble protein antigens immunized intranasally stimulate low levels of immune responses if not being used with adjuvants. So, the use of immunological adjuvant plays a significant role in mucosal immunity. With regard to antigens, immunization routes and specificity of anti-infection, properties of specific adjuvants may vary essentially. There has been no research report on the intranasal immunization route of sperm antigens and the application of immunological adjuvants at home or abroad.This study for the first time used cytokine IL-5 as the immunological adjuvant for intranasal immunization of sperm protein Spl7. Sperm protein Spl7 was cloned and prokaryotically expressed using genetic recombination technique. cDNA sequence encoding IL-5 protein in mature mice was inserted into prokaryotic expression vector pET/SP17 to construct recombinant expression vector of IL-5-Spl7 fusion gene, and then the IL-5-Spl7 fusion protein was prokaryotically expressed efficiently and purified. Male mice were intranasally immunized with resultant recombinant protein. Then the following data were observed: 1 The titer changes of anti-SP17antibody in serum and the reproductive
tract, 2 The effects on fertility, 3 Pathologic changes of vital organs such as the liver, kidney, spleen, lung, brain, testis and ovary, and 4 Changes in the rates of teratism and micronucleus of sperms in filial generation.The main results and conclusion of the study are as follow:1. cDNA sequence encoding sperm protein Spl7 was amplified from mice testis using RT-PCR. Recombinant plasmid pET/Spl7 was constructed by inserting the gene in the expression vector pET-28a(+) using oriented cloning. Full-length mice IL-5 gene was amplified with plasmid pGEM-l-IL-5 as the template and cloned into pET/Spl7 via the restriction sites of BamH I and Hind HI and linked to the upstream of Spl7 gene via the base sequence encoding the linker YPQD, thus successfully constructing recombinant plasmid pET/IL-5-Spl7. The fusion gene of IL-5-Spl7 was confirmed to meet the design requirements using double enzymatic excision and sequencing.2. The recombinant plasmids pET/Spl7 and pET/IL-5-Spl7 were transfected into E. Coli BL21(DE3). IPTG was used to stimulate gene expression. SDS-PAGE analysis revealed that both Spl7 and IL-5-Spl7 were expressed, and the molecular weight of the proteins were approximately 25kD and 49kD respectively, being approximate to the theoretical values of Spl7 and IL-5-Spl7 recombinant proteins. The purity of recombinant proteins Spl7 and IL-5-Spl7 was 88.9% and 91% respectively after being purified using Ni2+-ANT affinity column. Western blotting confirmed that the expressed proteins were Spl7 and IL-5-Spl7 respectively using anti-his mAb.3. The mice were immunized intranasally with the recombinant proteins and the titers of specific antibodies IgG and IgA in serum and the reproductive tract were determined. At 2 weeks of the primary immunization, Spl7-specific antibody IgG response was present in the mice of the experimental groups. Following immunization, antibody titers increased as the time elapsed and reached a peak at 6 weeks of the primary immunization. The highest levels of induced anti-Spl7 antibody were observed in the IL-5-Spl7 group, reaching 1:12800, which sustained for about 4 weeks before slight decrease. At 2 weeks of the primary immunization, specific antibody IgA was present in mice vaginal irrigation fluid of each experimental group and the levels increased by degrees, reaching peak values at 6 weeks of the primary immunization. The highest levels of antibody were observed in the IL-5-Spl7 group, reaching 1:12800. No Spl7-specific IgG or IgA antibody was detected in the negative control group. Rank sum testing showed that from 4 weeks after the primary
immunization, the titers of specific IgG and IgA antibodies in both the IL-5-Spl7 group and the Spl7+IL-5 group were significantly higher than that in the Spl7 group at the same stage(p<0.05), and that there was no significant difference between the !L-5-Spl7 group and the Spl7+IL-5 group.4. At 10 days of immunization, detection of the proliferation rate of mice splenic lymphocyte and IL-4 and INF- Y secreted by lymphocytes showed that, following immunization of IL-5-Spl7, the proliferation rate of mice splenic lymphocyte increased, so did the IL-4 and INF- Y in supernatant of lymphocyte culture. Moreover, the increase in IL-4 was much more obvious. Analysis of mice serum subtypes revealed that, following IL-5-Spl7 immunization, the ratio of IgGl:IgG2a increased. The above findings suggested that intranasal immunization with IL-5-Spl7 stimulated strong mucosal immunity in the reproductive tract and systemic immune response in mice, which mainly stimulated Tl^-type immune response, helping humoral immune response.5. Following intranasal immunization, the pregnancy rates of the groups IL-5-Spl7, IL5+Spl7, Spl7 decreased to 15.4%, 28.6%, $10% respectively. The number of newborn per birth in each group decreased too, significantly lower than that of the Spl7 group. These findings demonstrated that sperm antigen Spl7 with or without the use of adjuvant stimulated immunological contraceptive effects to certain degrees, but cannot totally block mice reproduction.6. Histologic studies following immunization revealed: 1 There was no apparent pathologic changes in the liver and spleen and no signs of lymphocyte infiltration, 2 There were perivascular spaces in brain, 3 There was no apparent pathologic changes in the kidney and lung, 4 The follicles were morphologically normal and no atrophy occurred, 5 The diameters of testis seminiferous tubules were normal with complete basal lamina, and there were abundant sperms and spermatoblasts of various stages. Micronucleus tests of bone marrow obtained from immunized mice and their offspring showed that there was no significant difference in PCE / NCE and micronucleus rate between the experimental and normal groups.
引文
1. UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Reserch Training in Human Reproduction.Research on reproductive health at WHO:biennial report 2000-2001 {M}.Geneva: World Health Organization.2002:9,22-23.
2.顾德伟.正确处理人口数量与资源使用关系[N].人民日报,2001-7-11(7).
3. NaZ RK, Vanek CM.Testis-specific proteins and their role in contraceptive vaccine development.Frontier in Bioscience, 1998,3:e39-48.
4. Evans JP.Sperm disintegfins, egg integrins, and other cell adhesion molecules of mammalian gamete plasma menbrane interactions.Frontiers in Bioscience, 1999,4:114-131.
5. Sabeur K, Foristall K, Ball BA.Characterization of PH-20 in canine spermatozoa and testis.Theriogenology, 2002,57:977-987.
6. NaZ RK,Chauhuan SC.Human sperm-specific peptide vaccine that causes long-term reversible contraception.Biol Reprod, 2002,67(2):674-80.
7. Gaudreaault C,Montfort L,Sullivan R.Effect of immunization of hamsters agarnst recombinant P26h on fertility rates.Reprod, 2002,123(2):307-13.
8. Goldberg E, VandeBerg JL, Mahony MC, et al.Immune response of male baboons to testis-specific LDH-C(4)[J].Contraception, 2001,64(2):93-98.
9. Kong M, Richard RT, Widgern EE,et al.Sequence and localization of mouse sperm autoantigenic protein Sp17.Biol Reprod, 1995,53:579-590.
10. Wen Y, Richardson RT, O 'Rand MD.Processing of the sperm protein Sp17 during the acrosome reaction and characterization as calmodulin binding protein.Dev Biol, 1999, 206:113-122.
11. Frayne J, Hall L. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction,2002,124(6):767-74.
12. Fujita A,Nakamura K,Kato T, et al.Ropporin,a sperm-specific binding protein of rhophilin,that is localized in the fibrouas sheath of sperm flagella.Cell Sci,2000,113(Pt 1):103-112.
13. Lea IA, Adoyo P, O'Rand MG. Autoimmunogenicity of the human sperm protein Sp17 in vasectomized men and identification of linear B cell epitopes. Fertil Steril. 1997,67(2):355-61.
14. Holmgren J.Mucosal immunity and vaccination. FEMS Micmbiol Immunol, 1991,4(1): 1-9.
15. Russell MW. Immunization for protection of the reproductive tract: a teview [J]. Am J Reprod Immunol, 2002, 47(5): 265-268.
16. Gockel CM, Bao S, Beagley KW. Trarsutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract [M]. Mol Immunol, 2000, 37 (9):537-544
17.石辛甫,高英杰,彭虹,等.双价痢疾菌苗株免疫小鼠后GALT中ASC的观察.免疫学杂志,1 998,1 4(4):23 1—232.
18. Pockley AG,Montgomery PC.In vivo adjuvant effect of interleukins 5 and 6 on rat tear IgA antibody responses[J].Immunology, 1991,73(1):19-23.
19. Alistair JR,Maija KC.Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo[J].Eur Immunol, 1993, 23(12): 3141 -3145.
20. Belinda LW, Robyn MS,Smith KL,et al.Enhancement of the specific mucosal IgA response in vivo by interleukin-5 expressed by an attenuated strain of Salmonella serotype Dublin[J].J Med Microbiol, 1997,46( 12): 1029-1038.
21.郭斐,陆柔剑,孙朝晖,等.IL-5在非复制重组痘苗病毒中的表达及其对重组病毒免疫效果的影响[J].病毒学报,2001,17(3):225-229.
22. Braciak TA,Gallichan WS,Graham FL,et al.Recombinant adenovirus vectors expressing interleukin-5 and -6 specifically enhance mucosal immunoglobulin A responses in the lung[J].Immunology,2000,101 (3):388-396.
23. Areas AP, Oliveira ML, Miyaji EN,et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun, 2004,321 (1): 192-196.
24. Lea IA,Richardson RT, Widgren EE,et al.Cloning and sequencing of cDNAs encoding the human spermprotein SP 17 [J]. Biochim Biophys Acta, 1996,1307(3) :263-266.
25. Richardson RT, Yamasaki N, O'rand MG.Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome rezcting.Dev Biol,1994,165(2):688-701.
26. Lea IA,Kurth B,O'Rand MG.Immune response to immunization with sperm antigens in the mazaque oviduct.Biol Reprod, 1998,58:794-800.
27. Adoyo PA, Lea IA, Richardson RT, et al. Sequence and characterization of the sperm protein Sp17 from the baboon. Mol Reprod Dev, 1997,47(1):66-71.
28. Huang X, Hu X, Gao Y. Expression of human ciliary neurotrophic factor gene in Escherichia coll. Zhonghua-Yi- Xue-Yi-Chuan-Xue-Za-Zhi. 1998 Apr 10; 15(2): 69-71.
29. Wei XC, Li H, Ji JG,et,al. Expression, purification and activity measurement of soluble BACE protein in E.coli. Sheng-Wu-Hua-Xue-2002 Jul; 34(4): 498-501.
30. Edgell MH, Sims DA, Pielak GJ, Yi E High-precision, high-throughput stability determinations facilitated by robotics and a semiautomated titrating fluorometer. Biochemistry. 2003 Jun 24; 42(24): 7587-93.
31.姜泊,张亚历,周殿元,主编.分子生物学常用实验方法[M]。北京:人民军医出版社,1998:56—64.
32.F,奥斯伯,R,布伦特,RE,金斯敦.精编分子生物学实验指南[M].北京:科学出版社,1998,332.
33. Naz RK, Rajesh C. Passive immunization for immunocontraception: lessons learned from infectious diseases. Front Biosci, 2004,9:2457-65.
34. Chen D, Huang Y. Advances in research on the target antigens of antisperm antibodies. Zhonghua Nan Ke Xue,2004,10(6) :458-60, 464.
35.黄宇烽,王一飞,赵金然,等.以免疫球蛋白为基础的避孕研究/设想.中华男科学,2000,6(1):6-10.
36. Sarinas SA, Chitkara RK. PET and SPECT in the management of lung cancer. Curr-Opin-Pulm-Med. 2002 Jul; 8(4): 257-64.
37. Zhang X, Guo P, Jing G. A vector with the downstream box of the initiation codon can highly enhance protein expression in Escherichia coli. Biotechnol-Lett. 2003 May; 25(10): 755-60.
38. Mootz HD, Blum ES, Tyszkiewicz AB, Muir TW. Conditional protein splicing: a new tool to control protein structure and function in vitro and in vivo. J-Am-Chem-Soc. 2003 Sep 3; 125(35): 10561-9.
39. Monteiro RA, Souza EM, Geoffrey YM, et,al. Expression, purification, and functional analysis of the C-terminal domain of Herbaspirillum seropedicae NifA protein. Protein-Expr-Purif 2003 Feb; 27(2): 313-8
40. Nunez E, Wei X, Delgado C, et al.Cloning, expression, and purification ofhistidine- tagged preS domains of hepatitis B virus.Protein Expr Purif, 2001, 21(1): 183-191.
41. Wang QS, Unrau PJ. Purification of histidine-tagged T7 RNA ligase from E. coli. Biotechniques. 2002, 33(6): 1256-60.
42. Ehrmann MA, Scheyhing CH, Vogel RF. In vitro stability and expression of green fluorescent protein under high pressure conditions. Lett-Appl-Microbiol 2001 Apr; 32(4): 230-4.
43. Pizza M,Giuliani MM,Fontana MR,et al.Mucosal vaccines:non toxic derivatives of LT and CT as mucosal adjuvants.Vaccine,2001,19(17-19):2534-2541.
44. Zurbriggen R, Metcalfe IC, Gluck R,et al. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev Vaccines. 2003 Apr;2(2):295-304.
45. Baudner BC, Giuliani MM, Verhoef JC,et al. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine. 2003 Sep 8;21 (25-26):3837-44.
46. Kang SM, Yao Q, Guo L, et al. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J Virol. 2003 Sep;77(18):9823-30.
47. Campos EA, Namikoshi J, Maeba S,et al. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant. J Oral Sci. 2003 Mar;45(1):25-31.
48. Bao S,Beagley KW, Murry A,et al.Intestinal IgA plasma cells of the Bl lineadge are IL-5 dependent[J].Immunology, 1998,94(2): 181. 49. Bao S,Beagley KW, Allanson M,et al.Exogenous interleukin-6 promotes enhanced IgA responses in vivo[J].Immunol cell Bio1,1998,76(6):560
50. Butter C,Lun A,Splettstoesser T, et al.Monclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions[J].Eur Resir J,2003,21 (5):799-803.
51. Thalhamer J,Leitner W, Hammerl P, et al.Designing immune responses with genetic immunization and immunostimulatory DNA sequences.Endocr Regul, 2001,35:143-166.
52.宴菊芳.DNA疫苗的分子佐剂研究进展.国外医学免疫学分册,2000,24:197-201.
53. Horton RM, Hunt HD,Ho SN,et al.Engineering hybrid genes without the use of restriction enzymes:Gene splicing by overlap extension.Gene, 1989,77(1):61-68.
54. Richard A, George, Jaap H, et al.An analysis of protein domain linkers: their classification and role in protein folding.Protein Engineering, 2002,15(11):871-879.
55.李育阳主编.基因表达技术。第一版,北京:科学出版社,2002,125-138.
56. Ariane R, Marita TB,Karin L,et al.B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues Role of adjuvants and routes of immunization.Vaccine,2003,21:458-467.
57. Boyaka PN, Tafaro A, Fischer R,et al. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr Pharm Des, 2003,9 (24): 1965-72.
58.徐辉,高英杰,石辛甫,等.免疫途径及侵袭蛋白表达对痢疾疫苗免疫效果影响的实验研究.中国微生物和免疫学杂志,2001,21(5):527-530。
59. Homer AAA, Ronaghy PM, Cheng MD, et al.Immunostimulatory DNA is a potent mucosal adjuvant.Cell Immunol, 1998,190:77-82.
60. McCluskie M J, Weeratna RD, Davis HL.The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.Vaccine, 2001,19:2657-2660.
61. Morris CB, Cheng E, Thanawastien A, et al.Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide(E7) in combination with the mucosal adjuvant LT(R192G).Vaccine, 18:1944-1951.
62. Tochikubo KM, Isaka M, Yasuda S, et al.Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.Vaccine, 1998,16:150-155.
63. Joseph A, Louria-Hayon I, Plis-Finarov A, et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine, 2002,20(27-28):3342-54.
64. Lavelle EC, McNeela E, Armstrong ME,et al. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J Immunol, 2003,171 (5):2384-92.
65. Klinguer C,Beck A,De-Lys P, et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine, 2001,19(30):4236-44.
66. Hilgers LA,Gherme L,Nicolas I,et al. Alkyl-polyacrylate esters are strong mucosal adjuvants.Vaccine,2000,18(28):3319-25.
67. Kyd JM, Foxwell AR, Cripps AW, et al.Mucosal immunity in the lung and upper airway.Vaccine, 2001,19(17-19):2527-2533.
68. Kodama S, Suenaga S, Hirano T, et al.Induction of specific immunoglobulin A and Th_2 immune responses to P6 outer membrane protein of non-typeable Haemophilus influenzae in middle ear mucosa by intranasal immunization.Infect Immun, 2000, 68(4):2294-2300.
69. Rock EP, Reich KA, Lyu DM, et al.Immunogenicity of a fusion protein linking the beta subunit carboxyl terminal peptide of human chorionic gonadotropin to the B subunit of Escherichia coli heat-labile enterotoxin.Vaccine,1996,14(16):1560-1568.
70. Jobling MG, Palmer LM, Erbe JL,et al.Construction and characterization of versatile cloning vectors for the efficient delivery of native foreign proteins to the periplasm of Escherichia colz.Plasmid, 1997,38(3): 158-173.
71. Lacour M, Arrighi JF, Muller KM,et al.cAMP up-regulates IL-4 and IL-5 production from activated CD4+T cell while decreasing IL-2 release and NF-AT induction.Int Immunol, 1994,6:1333-1343.
72. Xu-Amano J, Jackson RJ, Fujihashi K,et al.Helper Th_1 and Th_2cell responses following mucosal or systemic immunization with cholera toxin.Vaccine,1994,12:903-911.
73. Xu-Amano J,Kiyono H,Jackson RJ,et al.Helper T cell subsets for immunoglobulin A responses:oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th_2 cells in mucosa associated tissues.J Exp Med, 1993,178:1309-1320.
74. Romagnani S.Human Th_1 and Tb_2subsets:doubt no more.Immunol Tody, 1991,12: 256-257.
75. Sher A, Coffman RL.Regulation of immunity to parasiters by T cells and T cell-derived cytokines.Annu Rev Immunol, 1992,10:385-409.
76. Yssel H, Johnson KE, Schneider PV, et al.T cell activation-inducing epitopers of the house dust mite allergen Der p I proliferation and lymphokine production patterns by Der p I -specific CD4- T cell clones.J Immunol, 1992,148:738-745.
77. Coffman RL,Varkila K,Scott P,et al.Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo.Immunol Rev, 1991,123:189-207.
78. Lian T,Bui T,Ho RJ.Formulation of HIV-envelope protein with lipid vesicles
expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.Vaccine, 1999,18:604-611.
79. Spit BJ,Hendriksen EG,Bruijntjes JP, et al.Nasal lymphoid tissue in the rat.Cell Tissue Res,1989,255:193-198.
80. van der Ven I,Sminia.The development and structure of mouse nasal-associated lymphoid tissue:an immuno- and enzyme-histochemical study.Reg Immunol, 1993,5:69-75.
81. kuper CF, Koornstra PJ,Hameleers DM,et al.The role of nasopharyngeal lymphoid tissue.Immunol Tody, 1992,13:219-224.
82. Gallichan WS,Woolstencroft RN,Guarasci T, et al.Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increase IgA and protection against herpes simplex virus-2 in the genital tract.J Immunol,2001,166:3451-3457.
83. Hameleers DM,van der Ven I,Biewenga J,et al.Mucosal and systemic antibody formation in the rat after intranasal administration of three different antigens.Immunol Cell Biol, 1991,69:119-125.
84. Wu HY, Nguyen HH,Russell MW.Nasal lymphoid tissue(NALT) as a mucosal immune inductive site.Scand J Immunol, 1997,46:506-513.
85. Zhi QX, Susanna P, Hildegund CJE,et al. Induction of Genital Immunity by DNA Priming and Intranasal Booster Immunization with a Replication-Defective Adenoviral Recombinant. The Journal of Immunology, 1999, 162:6716-6723.
86.张桥.卫生毒理学基础[M].北京:人民卫生出版社,2000:249-285.
87. Rojas-Hemandez, Rodriguez-Monroy MA, et al.Intranasal coadministration of the CrylAc protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis.Infect Immun, 2004,72(8):4368-75.
88. Apostolaki M, Williams NA. Nasal delivery of antigen with the B subunit of Escherichia coli heat-labile enterotoxin augments antigen-specific T-cell clonal expansion and differentiation.Infect Immun. 2004,72(7):4072-80.
89. Bowe F, Lavelle EC, McNeela EA,et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun, 2004,72(7):4052-60.
90. Isaka M, Komiya T, Takahashi M,et al. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine, 2004,22(23-24):3061-8.
91. Kim TG, Gruber A, Langridge WH. HIV-1 gpl20 V3 cholera toxin B subunit fusion gene expression in transgenic potato.Protein Expr Purif, 2004,37(1): 196-202.
92. Sanchez AE, Aquino G, Ostoa-Saloma P,et al. Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th_1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine. Clin Diagn Lab Immunol, 2004,
93. Areas AP, Oliveira ML, Miyaji EN, et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice.Biochem Biophys Res Commun, 2004,321(1): 192-6.
94. Kim TG, Gruber A, Ruprecht RM, et al. Synthesis and Assembly of SIVmac Gag p27 Capsid Protein Cholera Toxin B Subunit Fusion Protein in Transgenic Potato.Mol Biotechnol, 2004,28(l):33-40.
95. Yan J, Wang Y, Shao SH, et al. Construction of prokaryotic expression system of ltB-ureB fusion gene and identification of the recombinant protein immunity and adjuvanticity. World J Gastroenterol, 2004,10(18):267
96. Kang TJ, Han SC, Jang MO, et al. Enhanced expression of B-subunit of Escherichia coli heat-labile enterotoxin in tobacco by optimization of coding sequence.Appl Biochem Biotechnol.,2004,117(3): 175-87.
97. Wagner B, Hufnagl K, Radauer C, et al. Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant.J Immunol Methods, 2004,287(1-2):203-15.
98. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun. 2003 Aug;71(8):4780-8.
99. Kokuryo S, Inoue H, Fukuizumi T,et al. Evaluation of interleukin 1 as a mucosal adjuvant in immunization with Streptococcus sobrinus cells by tonsillar application in
rabbits. Oral Microbiol Immunol, 2002,17(3): 163-71.
100. Moon BG, Takaki S, Miyake K,et al. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol, 2004,172(10):6020-9.
101. James W, Lillard JR, Prosper N, et al.RANTES potentiates antigen-specific mucosal immune respones.The Journal of Immunology, 2001,166:162-169.
102. Kang SM, Compans RW.Enhancement of mucosal immunization with Virus-Particles of simian immunodeficiency virus.J of Virology, 2003,77(6):3615-3623.
103. O'Hern PA,Bambra CS,Isahakia M,et al.Reversible contraception in female baboons immunized with a synthetic epitope of sperm-specific lactate dehydrogenase.Biol Reprod, 1995,52:331-339.
104. Sadler K,Bird PH,Brown L,et al.The antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens. Vaccine, 1999,18(5-6) :416-425.
105. O'hern PA,Liang ZG,Bambra CS,et al.Colinear synthesis of an antigen-specific B-cell epitope with a promiscuous tetanus toxin T-cell epitope:a synthetic peptide immunocontraceptive.Vaccine, 1997,15(16): 1761-1766.
106. Naz RK, Zhu X,Kadam AL.Identification of human sperm peptide sequence involved in egg binding for immunocontraception.Biol Reprod,2000,62:318-324.
107. Tung KSK,Primakoff P, Woolman-Gamer L, et al.Mechanism of infertility in male guinea pigs immunized with sperm PH-20.Biol Reprod, 1997,56:1133-1141.
108. Lou YH, Ang J, Thai H, et al.A zona pellucida 3 peptide vaccine induceds antibodies and reversible infertility without ovarian pathology.J Immunol, 1995,155:2715-2720.
109. Haas GJr, Bronson RA, Cruz OJ,et al.Antisperm antibody and infertility.In:Bronson RA, Alexander NJ, Anderson D, et al.(eds), Reproductive Immunology.Blackwell science publisher, 1996,171-211.
110. Bronson RA, Cooper GW, Rosenfeld D.Sperm antibodies: their role in infertility.Fertil Steril, 1980,42:171-183.
111.刘毓谷.卫生毒理学基础[M].北京:人民卫生出版社,1987,198-199.
112.曹佳,林真(日本),余真平.微核实验[M].北京:军事医学科学出版社,2000,42-64.
113.曹佳.微核实验[M].北京:军事医学科学出版社,第一版,13-15.
2.顾德伟.正确处理人口数量与资源使用关系[N].人民日报,2001-7-11(7).
3. NaZ RK, Vanek CM.Testis-specific proteins and their role in contraceptive vaccine development.Frontier in Bioscience, 1998,3:e39-48.
4. Evans JP.Sperm disintegfins, egg integrins, and other cell adhesion molecules of mammalian gamete plasma menbrane interactions.Frontiers in Bioscience, 1999,4:114-131.
5. Sabeur K, Foristall K, Ball BA.Characterization of PH-20 in canine spermatozoa and testis.Theriogenology, 2002,57:977-987.
6. NaZ RK,Chauhuan SC.Human sperm-specific peptide vaccine that causes long-term reversible contraception.Biol Reprod, 2002,67(2):674-80.
7. Gaudreaault C,Montfort L,Sullivan R.Effect of immunization of hamsters agarnst recombinant P26h on fertility rates.Reprod, 2002,123(2):307-13.
8. Goldberg E, VandeBerg JL, Mahony MC, et al.Immune response of male baboons to testis-specific LDH-C(4)[J].Contraception, 2001,64(2):93-98.
9. Kong M, Richard RT, Widgern EE,et al.Sequence and localization of mouse sperm autoantigenic protein Sp17.Biol Reprod, 1995,53:579-590.
10. Wen Y, Richardson RT, O 'Rand MD.Processing of the sperm protein Sp17 during the acrosome reaction and characterization as calmodulin binding protein.Dev Biol, 1999, 206:113-122.
11. Frayne J, Hall L. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction,2002,124(6):767-74.
12. Fujita A,Nakamura K,Kato T, et al.Ropporin,a sperm-specific binding protein of rhophilin,that is localized in the fibrouas sheath of sperm flagella.Cell Sci,2000,113(Pt 1):103-112.
13. Lea IA, Adoyo P, O'Rand MG. Autoimmunogenicity of the human sperm protein Sp17 in vasectomized men and identification of linear B cell epitopes. Fertil Steril. 1997,67(2):355-61.
14. Holmgren J.Mucosal immunity and vaccination. FEMS Micmbiol Immunol, 1991,4(1): 1-9.
15. Russell MW. Immunization for protection of the reproductive tract: a teview [J]. Am J Reprod Immunol, 2002, 47(5): 265-268.
16. Gockel CM, Bao S, Beagley KW. Trarsutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract [M]. Mol Immunol, 2000, 37 (9):537-544
17.石辛甫,高英杰,彭虹,等.双价痢疾菌苗株免疫小鼠后GALT中ASC的观察.免疫学杂志,1 998,1 4(4):23 1—232.
18. Pockley AG,Montgomery PC.In vivo adjuvant effect of interleukins 5 and 6 on rat tear IgA antibody responses[J].Immunology, 1991,73(1):19-23.
19. Alistair JR,Maija KC.Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo[J].Eur Immunol, 1993, 23(12): 3141 -3145.
20. Belinda LW, Robyn MS,Smith KL,et al.Enhancement of the specific mucosal IgA response in vivo by interleukin-5 expressed by an attenuated strain of Salmonella serotype Dublin[J].J Med Microbiol, 1997,46( 12): 1029-1038.
21.郭斐,陆柔剑,孙朝晖,等.IL-5在非复制重组痘苗病毒中的表达及其对重组病毒免疫效果的影响[J].病毒学报,2001,17(3):225-229.
22. Braciak TA,Gallichan WS,Graham FL,et al.Recombinant adenovirus vectors expressing interleukin-5 and -6 specifically enhance mucosal immunoglobulin A responses in the lung[J].Immunology,2000,101 (3):388-396.
23. Areas AP, Oliveira ML, Miyaji EN,et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun, 2004,321 (1): 192-196.
24. Lea IA,Richardson RT, Widgren EE,et al.Cloning and sequencing of cDNAs encoding the human spermprotein SP 17 [J]. Biochim Biophys Acta, 1996,1307(3) :263-266.
25. Richardson RT, Yamasaki N, O'rand MG.Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome rezcting.Dev Biol,1994,165(2):688-701.
26. Lea IA,Kurth B,O'Rand MG.Immune response to immunization with sperm antigens in the mazaque oviduct.Biol Reprod, 1998,58:794-800.
27. Adoyo PA, Lea IA, Richardson RT, et al. Sequence and characterization of the sperm protein Sp17 from the baboon. Mol Reprod Dev, 1997,47(1):66-71.
28. Huang X, Hu X, Gao Y. Expression of human ciliary neurotrophic factor gene in Escherichia coll. Zhonghua-Yi- Xue-Yi-Chuan-Xue-Za-Zhi. 1998 Apr 10; 15(2): 69-71.
29. Wei XC, Li H, Ji JG,et,al. Expression, purification and activity measurement of soluble BACE protein in E.coli. Sheng-Wu-Hua-Xue-2002 Jul; 34(4): 498-501.
30. Edgell MH, Sims DA, Pielak GJ, Yi E High-precision, high-throughput stability determinations facilitated by robotics and a semiautomated titrating fluorometer. Biochemistry. 2003 Jun 24; 42(24): 7587-93.
31.姜泊,张亚历,周殿元,主编.分子生物学常用实验方法[M]。北京:人民军医出版社,1998:56—64.
32.F,奥斯伯,R,布伦特,RE,金斯敦.精编分子生物学实验指南[M].北京:科学出版社,1998,332.
33. Naz RK, Rajesh C. Passive immunization for immunocontraception: lessons learned from infectious diseases. Front Biosci, 2004,9:2457-65.
34. Chen D, Huang Y. Advances in research on the target antigens of antisperm antibodies. Zhonghua Nan Ke Xue,2004,10(6) :458-60, 464.
35.黄宇烽,王一飞,赵金然,等.以免疫球蛋白为基础的避孕研究/设想.中华男科学,2000,6(1):6-10.
36. Sarinas SA, Chitkara RK. PET and SPECT in the management of lung cancer. Curr-Opin-Pulm-Med. 2002 Jul; 8(4): 257-64.
37. Zhang X, Guo P, Jing G. A vector with the downstream box of the initiation codon can highly enhance protein expression in Escherichia coli. Biotechnol-Lett. 2003 May; 25(10): 755-60.
38. Mootz HD, Blum ES, Tyszkiewicz AB, Muir TW. Conditional protein splicing: a new tool to control protein structure and function in vitro and in vivo. J-Am-Chem-Soc. 2003 Sep 3; 125(35): 10561-9.
39. Monteiro RA, Souza EM, Geoffrey YM, et,al. Expression, purification, and functional analysis of the C-terminal domain of Herbaspirillum seropedicae NifA protein. Protein-Expr-Purif 2003 Feb; 27(2): 313-8
40. Nunez E, Wei X, Delgado C, et al.Cloning, expression, and purification ofhistidine- tagged preS domains of hepatitis B virus.Protein Expr Purif, 2001, 21(1): 183-191.
41. Wang QS, Unrau PJ. Purification of histidine-tagged T7 RNA ligase from E. coli. Biotechniques. 2002, 33(6): 1256-60.
42. Ehrmann MA, Scheyhing CH, Vogel RF. In vitro stability and expression of green fluorescent protein under high pressure conditions. Lett-Appl-Microbiol 2001 Apr; 32(4): 230-4.
43. Pizza M,Giuliani MM,Fontana MR,et al.Mucosal vaccines:non toxic derivatives of LT and CT as mucosal adjuvants.Vaccine,2001,19(17-19):2534-2541.
44. Zurbriggen R, Metcalfe IC, Gluck R,et al. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev Vaccines. 2003 Apr;2(2):295-304.
45. Baudner BC, Giuliani MM, Verhoef JC,et al. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine. 2003 Sep 8;21 (25-26):3837-44.
46. Kang SM, Yao Q, Guo L, et al. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J Virol. 2003 Sep;77(18):9823-30.
47. Campos EA, Namikoshi J, Maeba S,et al. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant. J Oral Sci. 2003 Mar;45(1):25-31.
48. Bao S,Beagley KW, Murry A,et al.Intestinal IgA plasma cells of the Bl lineadge are IL-5 dependent[J].Immunology, 1998,94(2): 181. 49. Bao S,Beagley KW, Allanson M,et al.Exogenous interleukin-6 promotes enhanced IgA responses in vivo[J].Immunol cell Bio1,1998,76(6):560
50. Butter C,Lun A,Splettstoesser T, et al.Monclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions[J].Eur Resir J,2003,21 (5):799-803.
51. Thalhamer J,Leitner W, Hammerl P, et al.Designing immune responses with genetic immunization and immunostimulatory DNA sequences.Endocr Regul, 2001,35:143-166.
52.宴菊芳.DNA疫苗的分子佐剂研究进展.国外医学免疫学分册,2000,24:197-201.
53. Horton RM, Hunt HD,Ho SN,et al.Engineering hybrid genes without the use of restriction enzymes:Gene splicing by overlap extension.Gene, 1989,77(1):61-68.
54. Richard A, George, Jaap H, et al.An analysis of protein domain linkers: their classification and role in protein folding.Protein Engineering, 2002,15(11):871-879.
55.李育阳主编.基因表达技术。第一版,北京:科学出版社,2002,125-138.
56. Ariane R, Marita TB,Karin L,et al.B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues Role of adjuvants and routes of immunization.Vaccine,2003,21:458-467.
57. Boyaka PN, Tafaro A, Fischer R,et al. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr Pharm Des, 2003,9 (24): 1965-72.
58.徐辉,高英杰,石辛甫,等.免疫途径及侵袭蛋白表达对痢疾疫苗免疫效果影响的实验研究.中国微生物和免疫学杂志,2001,21(5):527-530。
59. Homer AAA, Ronaghy PM, Cheng MD, et al.Immunostimulatory DNA is a potent mucosal adjuvant.Cell Immunol, 1998,190:77-82.
60. McCluskie M J, Weeratna RD, Davis HL.The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.Vaccine, 2001,19:2657-2660.
61. Morris CB, Cheng E, Thanawastien A, et al.Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide(E7) in combination with the mucosal adjuvant LT(R192G).Vaccine, 18:1944-1951.
62. Tochikubo KM, Isaka M, Yasuda S, et al.Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.Vaccine, 1998,16:150-155.
63. Joseph A, Louria-Hayon I, Plis-Finarov A, et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine, 2002,20(27-28):3342-54.
64. Lavelle EC, McNeela E, Armstrong ME,et al. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J Immunol, 2003,171 (5):2384-92.
65. Klinguer C,Beck A,De-Lys P, et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine, 2001,19(30):4236-44.
66. Hilgers LA,Gherme L,Nicolas I,et al. Alkyl-polyacrylate esters are strong mucosal adjuvants.Vaccine,2000,18(28):3319-25.
67. Kyd JM, Foxwell AR, Cripps AW, et al.Mucosal immunity in the lung and upper airway.Vaccine, 2001,19(17-19):2527-2533.
68. Kodama S, Suenaga S, Hirano T, et al.Induction of specific immunoglobulin A and Th_2 immune responses to P6 outer membrane protein of non-typeable Haemophilus influenzae in middle ear mucosa by intranasal immunization.Infect Immun, 2000, 68(4):2294-2300.
69. Rock EP, Reich KA, Lyu DM, et al.Immunogenicity of a fusion protein linking the beta subunit carboxyl terminal peptide of human chorionic gonadotropin to the B subunit of Escherichia coli heat-labile enterotoxin.Vaccine,1996,14(16):1560-1568.
70. Jobling MG, Palmer LM, Erbe JL,et al.Construction and characterization of versatile cloning vectors for the efficient delivery of native foreign proteins to the periplasm of Escherichia colz.Plasmid, 1997,38(3): 158-173.
71. Lacour M, Arrighi JF, Muller KM,et al.cAMP up-regulates IL-4 and IL-5 production from activated CD4+T cell while decreasing IL-2 release and NF-AT induction.Int Immunol, 1994,6:1333-1343.
72. Xu-Amano J, Jackson RJ, Fujihashi K,et al.Helper Th_1 and Th_2cell responses following mucosal or systemic immunization with cholera toxin.Vaccine,1994,12:903-911.
73. Xu-Amano J,Kiyono H,Jackson RJ,et al.Helper T cell subsets for immunoglobulin A responses:oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th_2 cells in mucosa associated tissues.J Exp Med, 1993,178:1309-1320.
74. Romagnani S.Human Th_1 and Tb_2subsets:doubt no more.Immunol Tody, 1991,12: 256-257.
75. Sher A, Coffman RL.Regulation of immunity to parasiters by T cells and T cell-derived cytokines.Annu Rev Immunol, 1992,10:385-409.
76. Yssel H, Johnson KE, Schneider PV, et al.T cell activation-inducing epitopers of the house dust mite allergen Der p I proliferation and lymphokine production patterns by Der p I -specific CD4- T cell clones.J Immunol, 1992,148:738-745.
77. Coffman RL,Varkila K,Scott P,et al.Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo.Immunol Rev, 1991,123:189-207.
78. Lian T,Bui T,Ho RJ.Formulation of HIV-envelope protein with lipid vesicles
expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.Vaccine, 1999,18:604-611.
79. Spit BJ,Hendriksen EG,Bruijntjes JP, et al.Nasal lymphoid tissue in the rat.Cell Tissue Res,1989,255:193-198.
80. van der Ven I,Sminia.The development and structure of mouse nasal-associated lymphoid tissue:an immuno- and enzyme-histochemical study.Reg Immunol, 1993,5:69-75.
81. kuper CF, Koornstra PJ,Hameleers DM,et al.The role of nasopharyngeal lymphoid tissue.Immunol Tody, 1992,13:219-224.
82. Gallichan WS,Woolstencroft RN,Guarasci T, et al.Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increase IgA and protection against herpes simplex virus-2 in the genital tract.J Immunol,2001,166:3451-3457.
83. Hameleers DM,van der Ven I,Biewenga J,et al.Mucosal and systemic antibody formation in the rat after intranasal administration of three different antigens.Immunol Cell Biol, 1991,69:119-125.
84. Wu HY, Nguyen HH,Russell MW.Nasal lymphoid tissue(NALT) as a mucosal immune inductive site.Scand J Immunol, 1997,46:506-513.
85. Zhi QX, Susanna P, Hildegund CJE,et al. Induction of Genital Immunity by DNA Priming and Intranasal Booster Immunization with a Replication-Defective Adenoviral Recombinant. The Journal of Immunology, 1999, 162:6716-6723.
86.张桥.卫生毒理学基础[M].北京:人民卫生出版社,2000:249-285.
87. Rojas-Hemandez, Rodriguez-Monroy MA, et al.Intranasal coadministration of the CrylAc protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis.Infect Immun, 2004,72(8):4368-75.
88. Apostolaki M, Williams NA. Nasal delivery of antigen with the B subunit of Escherichia coli heat-labile enterotoxin augments antigen-specific T-cell clonal expansion and differentiation.Infect Immun. 2004,72(7):4072-80.
89. Bowe F, Lavelle EC, McNeela EA,et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun, 2004,72(7):4052-60.
90. Isaka M, Komiya T, Takahashi M,et al. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine, 2004,22(23-24):3061-8.
91. Kim TG, Gruber A, Langridge WH. HIV-1 gpl20 V3 cholera toxin B subunit fusion gene expression in transgenic potato.Protein Expr Purif, 2004,37(1): 196-202.
92. Sanchez AE, Aquino G, Ostoa-Saloma P,et al. Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th_1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine. Clin Diagn Lab Immunol, 2004,
93. Areas AP, Oliveira ML, Miyaji EN, et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice.Biochem Biophys Res Commun, 2004,321(1): 192-6.
94. Kim TG, Gruber A, Ruprecht RM, et al. Synthesis and Assembly of SIVmac Gag p27 Capsid Protein Cholera Toxin B Subunit Fusion Protein in Transgenic Potato.Mol Biotechnol, 2004,28(l):33-40.
95. Yan J, Wang Y, Shao SH, et al. Construction of prokaryotic expression system of ltB-ureB fusion gene and identification of the recombinant protein immunity and adjuvanticity. World J Gastroenterol, 2004,10(18):267
96. Kang TJ, Han SC, Jang MO, et al. Enhanced expression of B-subunit of Escherichia coli heat-labile enterotoxin in tobacco by optimization of coding sequence.Appl Biochem Biotechnol.,2004,117(3): 175-87.
97. Wagner B, Hufnagl K, Radauer C, et al. Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant.J Immunol Methods, 2004,287(1-2):203-15.
98. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun. 2003 Aug;71(8):4780-8.
99. Kokuryo S, Inoue H, Fukuizumi T,et al. Evaluation of interleukin 1 as a mucosal adjuvant in immunization with Streptococcus sobrinus cells by tonsillar application in
rabbits. Oral Microbiol Immunol, 2002,17(3): 163-71.
100. Moon BG, Takaki S, Miyake K,et al. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol, 2004,172(10):6020-9.
101. James W, Lillard JR, Prosper N, et al.RANTES potentiates antigen-specific mucosal immune respones.The Journal of Immunology, 2001,166:162-169.
102. Kang SM, Compans RW.Enhancement of mucosal immunization with Virus-Particles of simian immunodeficiency virus.J of Virology, 2003,77(6):3615-3623.
103. O'Hern PA,Bambra CS,Isahakia M,et al.Reversible contraception in female baboons immunized with a synthetic epitope of sperm-specific lactate dehydrogenase.Biol Reprod, 1995,52:331-339.
104. Sadler K,Bird PH,Brown L,et al.The antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens. Vaccine, 1999,18(5-6) :416-425.
105. O'hern PA,Liang ZG,Bambra CS,et al.Colinear synthesis of an antigen-specific B-cell epitope with a promiscuous tetanus toxin T-cell epitope:a synthetic peptide immunocontraceptive.Vaccine, 1997,15(16): 1761-1766.
106. Naz RK, Zhu X,Kadam AL.Identification of human sperm peptide sequence involved in egg binding for immunocontraception.Biol Reprod,2000,62:318-324.
107. Tung KSK,Primakoff P, Woolman-Gamer L, et al.Mechanism of infertility in male guinea pigs immunized with sperm PH-20.Biol Reprod, 1997,56:1133-1141.
108. Lou YH, Ang J, Thai H, et al.A zona pellucida 3 peptide vaccine induceds antibodies and reversible infertility without ovarian pathology.J Immunol, 1995,155:2715-2720.
109. Haas GJr, Bronson RA, Cruz OJ,et al.Antisperm antibody and infertility.In:Bronson RA, Alexander NJ, Anderson D, et al.(eds), Reproductive Immunology.Blackwell science publisher, 1996,171-211.
110. Bronson RA, Cooper GW, Rosenfeld D.Sperm antibodies: their role in infertility.Fertil Steril, 1980,42:171-183.
111.刘毓谷.卫生毒理学基础[M].北京:人民卫生出版社,1987,198-199.
112.曹佳,林真(日本),余真平.微核实验[M].北京:军事医学科学出版社,2000,42-64.
113.曹佳.微核实验[M].北京:军事医学科学出版社,第一版,13-15.